Frontiers

Advancing Inflammatory Bowel Disease Treatment through Nutritional Interventions

In the realm of gastroenterology, inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), presents a significant therapeutic challenge due to its chronic ...

HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access ...

HEALWELL, in collaboration with Takeda Pharmaceutical, presented new AI generated and regulatory-grade real-world data (RWD) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at ...

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing ...